CN117297868A - Implantable tear delivery device - Google Patents
Implantable tear delivery device Download PDFInfo
- Publication number
- CN117297868A CN117297868A CN202311227874.6A CN202311227874A CN117297868A CN 117297868 A CN117297868 A CN 117297868A CN 202311227874 A CN202311227874 A CN 202311227874A CN 117297868 A CN117297868 A CN 117297868A
- Authority
- CN
- China
- Prior art keywords
- machine
- tear
- patient
- implantable
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001727 in vivo Methods 0.000 claims abstract description 42
- 210000003296 saliva Anatomy 0.000 claims abstract description 35
- 210000004561 lacrimal apparatus Anatomy 0.000 claims abstract description 24
- 238000000338 in vitro Methods 0.000 claims abstract description 23
- 238000004891 communication Methods 0.000 claims abstract description 8
- 206010033675 panniculitis Diseases 0.000 claims abstract description 5
- 210000004304 subcutaneous tissue Anatomy 0.000 claims abstract description 5
- 230000005540 biological transmission Effects 0.000 claims description 11
- 238000007726 management method Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 238000009736 wetting Methods 0.000 abstract description 14
- 230000000153 supplemental effect Effects 0.000 abstract description 12
- 239000000607 artificial tear Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000011241 protective layer Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 210000003681 parotid gland Anatomy 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229920002529 medical grade silicone Polymers 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
Embodiments of the present invention provide an implantable tear delivery device capable of efficiently and reliably providing supplemental wetting to the human eye, comprising: an in-vivo machine disposed in a patient and an in-vitro machine disposed outside the patient, and the in-vivo machine and the in-vitro machine are connected to each other, wherein the in-vivo machine comprises: an in-vivo host disposed in subcutaneous tissue of a patient's ear, having a micropump and a microprocessor connected to the micropump; a saliva conduit connected to a patient's parotid canal, connected to an inlet of the micropump; a tear conduit connected to the lacrimal gland of the patient, connected to an outlet of the micropump; a wireless energy receiving module; the extracorporeal machine comprises: a power supply unit including a wireless energy supply module corresponding to the wireless energy receiving module; and the regulation and control unit is in communication connection with the microprocessor.
Description
Technical Field
The invention relates to the technical field of medical appliances, in particular to an implantable tear conveying device.
Background
The lacrimal secretion system of human eye is composed of lacrimal gland, auxiliary lacrimal gland and conjunctival goblet cell, under normal state, the divided tears are about 0.5-0.6ml in 16 hours, when the lacrimal gland secretes lacrimal fluid function abnormality, the tears instability caused by the abnormal quantity or quality or fluid mechanics of lacrimal fluid can be caused, thus the eye is not adapted and visual dysfunction is caused, dry eye is formed, the eyes of light people are dry and itchy, have foreign body feeling, burning feeling, blurred vision, vision fluctuation and the like, and the serious people can cause corneal ulcer, perforation and even blindness.
Clinical treatment of patients with mild dry eye mainly comprises administration of artificial tear drop eyes, clinical treatment of patients with severe dry eye is difficult, and various treatment effects are not ideal. In the prior art, an artificial tear in a tear bag fixed to a patient is pressurized using a tear delivery pump so that the artificial tear is delivered to the ocular surface through a catheter, and is constantly lubricated. However, this approach has the following drawbacks:
1) The tear bag is fixed on the patient, so that the patient is inconvenient to move due to poor portability, and the tear bag has larger damage and pollution risks;
2) The length of the infusion catheter between the tear bag and the end of the infusion tube is 500-700mm, tear flow in the long catheter can be subjected to larger resistance, and the tear is unstable in transmission and excessive in energy consumption;
3) When a person is in different postures, the change of the height between the tear bag and the eyes can cause the change of the tear pressure, and tear cannot be stably transmitted;
4) The transmission of the artificial tear can not be adjusted in time according to the wetting degree of the ocular surface;
5) The tear bag needs to be periodically replenished with artificial tear.
Disclosure of Invention
Embodiments of the present invention provide an implantable tear delivery device that is capable of providing supplemental wetting to the human eye with high efficiency and reliability.
According to one aspect of the present invention, there is provided an implantable tear delivery device comprising an in-vivo machine disposed within a patient's body and an in-vitro machine disposed outside the patient's body, and the in-vivo machine and the in-vitro machine are connected to each other, wherein,
the in-vivo machine includes: an in-vivo host disposed in subcutaneous tissue of a patient's ear, having a micropump and a microprocessor connected to the micropump; a saliva conduit connected to a patient's parotid canal, connected to an inlet of the micropump; a tear conduit connected to the lacrimal gland of the patient, connected to an outlet of the micropump; a wireless energy receiving module;
the extracorporeal machine comprises: a power supply unit including a wireless energy supply module corresponding to the wireless energy receiving module; and the regulation and control unit is in communication connection with the microprocessor.
Preferably, in any of the embodiments,
an outlet of the tear duct at an end thereof connected to the lacrimal gland of the patient is provided with a semipermeable membrane allowing only one-way flow from the tear duct to the lacrimal gland of the patient.
Preferably, in any of the embodiments,
at least a portion of the outer surface of the extracorporeal machine is provided with a flexible buffer layer.
Preferably, in any of the embodiments,
the external surface of the external machine is provided with a concave shape which is adapted to the shape of the body surface of the patient.
Preferably, in any of the embodiments,
the regulation and control unit comprises: a speed adjusting knob for adjusting the saliva conveying speed.
Preferably, in any of the embodiments,
the regulation and control unit comprises: a transmission speed indicator light for displaying the saliva transmission speed.
Preferably, in any of the embodiments,
the power supply unit includes: an in vitro battery.
Preferably, in any of the embodiments,
the wireless energy supply module includes: a wireless energy supply circuit connected to the extracorporeal battery.
Preferably, in any of the embodiments,
the power supply unit includes: and the battery management circuit is used for managing the charge and discharge of the external battery.
Preferably, in any of the embodiments,
the regulation and control unit comprises: and the power indicator is used for indicating the residual power of the external battery.
The implantable tear delivery device provided by the embodiments of the present invention can efficiently and reliably provide supplemental wetting for the human eye.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following discussion will discuss the embodiments or the drawings required in the description of the prior art, and it is obvious that the technical solutions described in connection with the drawings are only some embodiments of the present invention, and that other embodiments and drawings thereof can be obtained according to the embodiments shown in the drawings without inventive effort for a person skilled in the art.
Fig. 1 is a schematic structural view of an implantable tear delivery device according to an embodiment of the present invention.
Detailed Description
The following description of the embodiments of the present invention will be made in detail with reference to the accompanying drawings, wherein it is apparent that the embodiments described are only some, but not all embodiments of the present invention. All other embodiments, which can be made by a person of ordinary skill in the art without the need for inventive faculty, are within the scope of the invention, based on the embodiments described in the present invention.
Embodiments of the present invention provide an implantable tear delivery device that is capable of providing supplemental wetting to the human eye with high efficiency and reliability.
The saliva of the human body is colorless and odorless, and the pH value is 6.6-7.1. The daily secretion of normal humans is about 1.0 to 1.5 liters. Wherein the water content is 80%, the organic substances mainly comprise mucin, mucopolysaccharide, sialyl amylase, lysozyme, immunoglobulin (IgA, igG, igM), blood group substances (a, B, H), urea, uric acid, free amino acids, etc., and the inorganic substances comprise Na + 、K + 、Ca 2+ 、Cl － 、HCO 3 － And some gas molecules. In contrast, ions in human tears contain Na + 、K + 、Cl － The concentration is higher than that of serum, and a small amount of glucose and urea are also present, the pH value is 5.20-8.35, and the average pH value is 7.35. Thus, when the lacrimal gland of a human is problematic and difficult to secrete tear, saliva can be transported to the lacrimal gland by establishing a transport pipeline to replace tear to moisten the ocular surface.
According to one aspect of the present invention, there is provided an implantable tear delivery device comprising an in-vivo machine disposed within a patient's body and an in-vitro machine disposed outside the patient's body, and the in-vivo machine and the in-vitro machine are connected to each other, wherein,
the in-vivo machine includes: an in-vivo host disposed in subcutaneous tissue of a patient's ear, having a micropump and a microprocessor connected to the micropump; a saliva conduit connected to a patient's parotid canal, connected to an inlet of the micropump; a tear conduit connected to the lacrimal gland of the patient, connected to an outlet of the micropump; a wireless energy receiving module;
the extracorporeal machine comprises: a power supply unit including a wireless energy supply module corresponding to the wireless energy receiving module; and the regulation and control unit is in communication connection with the microprocessor.
In this way, saliva can be extracted from the patient's parotid canal by the micropump in the in vivo machine and delivered to the patient's lacrimal gland via the lacrimal catheter as a supplemental aid to tear fluid to provide supplemental wetting to the human eye to avoid human damage caused by dry eyes.
In addition, the external machine and the internal machine are mutually connected (for example, are mutually and magnetically connected through corresponding magnetic structures), on one hand, power can be supplied to the corresponding wireless energy receiving module of the internal machine through the wireless energy supply module of the power supply unit of the external machine, and on the other hand, communication connection between the external machine regulating and controlling unit and the microprocessor of the internal machine can be realized, so that saliva flow conveying can be regulated and controlled better, and the human eyes can be supplemented with wetting according to requirements.
Under the condition, the artificial tear bag with large damage risk and longer infusion line does not need to be carried about, the artificial tear bag does not need to be supplemented with the artificial tear regularly, and the human eyes can be supplied and lubricated stably and reliably by supplementing and wetting saliva generated by the human body.
Therefore, the implantable tear delivery device provided by the embodiments of the invention can efficiently and reliably provide supplementary wetting for human eyes.
Preferably, in any embodiment, the outlet of the end of the tear duct connected to the patient's lacrimal gland is provided with a semipermeable membrane allowing only unidirectional flow from the tear duct to the patient's lacrimal gland. Thus, saliva can be ensured to flow into lacrimal glands of patients only from the lacrimal duct and cannot flow back reversely, so that pollution or infection caused by external pathogenic microorganisms, bacteria and the like entering the lacrimal duct can be effectively prevented.
Optionally, in either embodiment, a resilient wire or mesh or spiral structure is attached to or embedded in the wall of the saliva conduit. Thus, the shape of the saliva conduit can be effectively maintained to prevent blockage caused by excessive bending.
Optionally, in either embodiment, the tear conduit wall is attached to or embeds a resilient wire or mesh or spiral structure. Thus, the shape of the tear duct can be effectively maintained, so that blockage caused by excessive bending of the tear duct can be prevented.
Optionally, in any embodiment, the saliva conduit comprises an elastic tube section. In this way, the saliva conduit may be adapted to flex as needed to avoid or reduce the risk of the conduit breaking, fracturing or becoming detached from the parotid gland tube in an unexpected situation (e.g., when subjected to external forces causing movement of portions of the body).
Optionally, in any embodiment, the tear conduit comprises an elastic tube segment. In this way, the tear conduit may be adapted to flex as needed to avoid or reduce the risk of the conduit breaking, fracturing, or becoming detached from the lacrimal gland in an unexpected situation (e.g., when subjected to external forces that cause movement of portions of the body).
Alternatively, in any of the embodiments, the elastic tube segment may comprise part of a bellows structure.
Alternatively, in either embodiment, the end of the saliva conduit that is connected to the parotid tube may have a larger diameter curled portion that is located within the parotid tube. In this way, the saliva tube is prevented from being accidentally detached from the parotid gland tube.
Alternatively, in either embodiment, the end of the tear conduit that is connected to the lacrimal gland may have a larger diameter curled portion located within the lacrimal gland. In this way, the tear duct may be prevented from inadvertently detaching from within the lacrimal gland.
Optionally, in any embodiment, the in-vivo machine comprises an in-vivo magnetic structure and the out-of-body machine comprises an out-of-body magnetic structure magnetically coupled to the in-vivo magnetic structure such that the in-vivo machine and the out-of-body machine are in adsorptive connection with each other through the magnetic coupling.
Preferably, in any embodiment, the in vivo magnetic structure comprises an in vivo permanent magnet.
Preferably, in any embodiment, the external magnetic structure comprises an external permanent magnet.
In this case, the external machine may be magnetically coupled (adsorbed) to the internal magnetic structure of the internal machine by an external permanent magnet. It will be appreciated that in the magnetically coupled state, the in-vivo magnetic structure and the in-vitro magnetic structure are spaced apart by the patient's skin tissue, but this does not affect the effective magnetic coupling therebetween, thereby allowing the in-vitro machine to be reliably magnetically coupled or magnetically attracted to the in-vivo machine.
Optionally, in any embodiment, the external magnetic structure comprises an external electromagnet. Therefore, the magnetic force intensity of the external magnetic structure can be adjusted according to the needs, and the external magnetic structure can adapt to the individual needs of patients to improve the safety and the comfort of the patients on the premise of ensuring that the external machine is reliably magnetically connected with the internal machine. On the other hand, if desired (for example, when there is no need to provide the human eye with supplementary humidification, or when maintenance of the in-vivo machine is required, or when charging of the in-vitro machine is required, or when examination of skin tissue clamped between the in-vivo machine and the in-vitro machine is required), the power supply to the in-vitro electromagnet can be reduced or eliminated so that the magnetic force thereof can be reduced or eliminated, so that the in-vitro machine can be conveniently removed from the in-vivo machine for corresponding operation.
Optionally, in any embodiment, the external surface of the external body that is aligned with the internal magnetic structure of the internal body has a concave shape that conforms to the shape of the patient's body surface.
Optionally, in any embodiment, the external surface of the external body that is aligned with the internal magnetic structure of the internal body has an elastic layer thereon.
Optionally, in any embodiment, the external machine is provided with a hook that can be hooked to the auricle of the patient. In this way, the extracorporeal machine may be further reliably positioned to reduce or eliminate the risk of accidental detachment of the extracorporeal machine (e.g., in the case of a user performing a sport).
Optionally, in any embodiment, the hook is an elastic hook.
Optionally, in any embodiment, the hook is removably disposed on the extracorporeal machine. In this way, the hook may be used as an optional accessory for the user's choice (e.g., in the case of a user performing an exercise), and may be removed when not needed.
Preferably, in any embodiment, the regulatory unit comprises: a speed adjusting knob for adjusting the saliva conveying speed. Thus, the user (e.g., patient) can adjust the saliva transfer rate up or down as needed to accommodate the need for supplemental wetting by personnel, including automatic or manual adjustments. For example, in case of an air-wet rainy day or a high ambient humidity, the saliva transfer speed may be reduced.
Optionally, in any embodiment, the regulating unit comprises a manual control knob. Thus, the user (e.g. patient) can manually adjust the saliva conveying speed or stop the saliva conveying according to the dryness/wetness degree of eyes, so as to adapt to the requirement of the person for supplementing the wetness. For example, in air-wet rainy days, saliva transport may be slowed or stopped.
Preferably, in any embodiment, the regulatory unit comprises: a transmission speed indicator light for displaying the saliva transmission speed.
Preferably, in any embodiment, the power supply unit includes: an in vitro battery.
Optionally, in any embodiment, the external battery comprises a detachable battery.
Optionally, in any embodiment, the in vitro battery comprises: a rechargeable battery built in the power supply unit.
Alternatively, in any embodiment, the in vitro battery comprises a lithium ion battery.
Preferably, in any embodiment, the wireless energy supply module comprises: a wireless energy supply circuit connected to the extracorporeal battery.
Optionally, in any embodiment, the wireless energy supply circuit comprises a wireless energy transmitting coil. In this case, the wireless energy transmitting coil may transmit electromagnetic waves to a wireless energy receiving module of the internal body machine (e.g., a wireless energy receiving coil thereof) by means of magnetic resonance, to supply electromagnetic energy thereto.
Optionally, in any embodiment, the wireless energy transmission coil comprises an inductive coil. In this way, the in-vivo machine can be wirelessly powered in a manner similar to the wireless charging of a cell phone.
Preferably, in any embodiment, the power supply unit includes: and the battery management circuit is used for managing the charge and discharge of the external battery.
Optionally, in any embodiment, the battery management circuit is configured to control direct current (DC-DC) conversion.
Preferably, in any embodiment, the regulatory unit comprises: and the power indicator is used for indicating the residual power of the external battery.
Optionally, in any embodiment, the wireless energy receiving module of the in-vivo machine includes a wireless energy receiving circuit, the wireless energy receiving circuit including: wireless energy receiving coil, rectification, filter circuit and DC-DC voltage conversion circuit. Thus, the wireless energy receiving circuit uses a resonant wireless energy transmission technology, receives electromagnetic wave energy sent by a wireless energy supply module (such as a wireless energy sending coil) of the external machine through the wireless energy receiving coil, converts the electromagnetic wave energy into induced electromotive force in the coil, and outputs proper working voltages (such as 3.3V direct current voltage which can comprise 3.3V direct current voltage which is supplied by a microprocessor circuit of the internal machine, +15V and-15V which are supplied by a micropump driving circuit) through rectification, a filter circuit and DC-DC voltage conversion.
Optionally, in any embodiment, the extracorporeal machine comprises: a wired charging interface. In this way, the power supply unit of the external machine (for example its external battery, in particular a rechargeable secondary battery) can be charged to replenish energy by wired charging when needed or appropriate.
Optionally, in any embodiment, the in-vivo machine comprises: a wired power interface extending to the user's body surface that connects to the in-body host. In this way, the wired power interface is provided on the user's body surface and can be wired to an external power source to recharge the in-vivo machine when needed (e.g., when the wireless charging mode implemented by the in-vitro machine fails or is blocked).
Optionally, in any embodiment, a closure cap or closure plug is provided on the wired power interface. In this way, the wired power interface is prevented from being damaged or contaminated when not in use.
Optionally, in any embodiment, a relief recess aligned with the wired power interface is provided on an outer surface of the extracorporeal machine. In this way, the risk of contact and damage to the wired power interface can be avoided when the external machine is attached (adsorbed or connected) to the internal machine.
Optionally, in any embodiment, the in-vivo machine comprises a connection hole extending to a body surface of the user, the in-vitro machine being mechanically connected to the in-vivo machine through the connection hole. In this way, the external machine can be attached to the internal machine more firmly and reliably.
Optionally, in any embodiment, the wired power interface is disposed within the connection aperture, and the external machine is mechanically connected to the internal machine through the wired power interface. Therefore, the connecting hole can realize the mechanical connection of the internal machine and the external machine and can also provide a wired power supply mode.
Optionally, in any embodiment, the external machine is connected to the internal machine by a threaded structure.
Optionally, in any embodiment, the wired power interface has internal threads, and the external machine is connected to the internal machine by a threaded structure inserted into the wired power interface.
Optionally, in any embodiment, the external machine is connected to the internal machine by a snap-fit structure.
Alternatively, in any embodiment, the micropump comprises a piezoelectric diaphragm pump.
Optionally, in any embodiment, the extracorporeal machine comprises a cooperative processor connected to the power supply unit and the regulation unit.
Optionally, in any embodiment, the cooperating processor of the external machine is communicatively coupled to a microprocessor of the internal machine.
Optionally, in any embodiment, the cooperating processor of the external machine and the microprocessor of the internal machine comprise a timer. In this way, the patient's human eye can be provided with supplemental wetness periodically and periodically without manual manipulation.
Optionally, in either embodiment, saliva flow is provided at regular time intervals by a timer to achieve supplemental wetting of the human eye.
Optionally, in either embodiment, saliva flow is provided by a timer according to a predetermined time schedule to achieve supplemental wetting of the human eye. In this way, the supply of saliva flow may be slowed or stopped during periods of time when the human eye is not prone to dryness (e.g., during sleep) to accommodate the needs of the patient's application.
Optionally, in any embodiment, the in-vivo machine comprises: a humidity sensor located at the lacrimal gland for measuring the patient's ocular surface humidity is connected to the microprocessor via a sensor lead. Thus, the saliva amount transmitted to the lacrimal gland can be controlled according to the ocular surface humidity data collected by the humidity sensor, and the in-vivo host controls the saliva transmission speed according to the ocular surface humidity data, so that the ocular surface humidity is regulated to be kept constant, and the ocular surface lubrication is kept. It will be appreciated that the portion of the humidity sensor that contacts the patient's ocular surface may be made from a medical-safe, flexible biocompatible material as used in the prior art to ensure safety in use.
Optionally, in any embodiment, the sensor lead and tear conduit are at least partially encapsulated together.
Optionally, in any embodiment, the extracorporeal machine comprises an ambient humidity sensor for measuring ambient humidity. In this way, the supplemental wetting of the human eye can be appropriately adjusted according to the influence of environmental humidity factors. For example, saliva flow may be slowed or stopped during periods of time when the human eye is not prone to desiccation (e.g., during sleep) to accommodate patient application needs.
Optionally, in any embodiment, a flexible buffer layer is provided on at least a portion of an outer surface (e.g., a portion facing a user) of the extracorporeal machine. In this way, a moderately elastic buffer may be provided when the external machine is adsorbed (connected) to the internal machine, to avoid or reduce the risk of damaging the user's skin.
Optionally, in any embodiment, the flexible buffer layer is made of silicone. In this way, the silica gel material (such as medical silica gel material, especially the silica gel material implantable in human body in the prior art) has good biocompatibility, no irritation, no toxicity and no allergic reaction to human tissues, thereby effectively improving the safety and comfort of users.
Optionally, in any embodiment, a silicone protective layer is disposed on at least a portion of an outer surface of the in-vivo machine. In this way, a moderately elastic buffer may be provided when the in-vivo machine is placed in position within the user's body to avoid or reduce the risk of damage to the user's tissue.
Optionally, in either embodiment, the silicone protective layer is made of medical grade silicone (especially silicone materials that are implantable in humans as in the prior art). Therefore, the silica gel protective layer has good biocompatibility, no irritation, toxicity and anaphylactic reaction to human tissues, little rejection reaction of organisms, good physical and chemical properties, can keep the original elasticity and softness in the process of contacting body fluid and tissues, is not degraded, is a quite stable inert substance, and avoids or reduces the risk of injury of users in the use process, thereby improving the use safety. In addition, the silica gel protective layer can also improve the stability of related communication or power supply circuit structures (such as parallel resonance circuits), so that the use is safer and more reliable.
Optionally, in either embodiment, at least a portion of the various components of the body (e.g., host, saliva conduit, tear conduit, etc.) are made of a polymer material having good biocompatibility, such as including polylactic acid (PLA) or Polycaprolactone (PCL), etc., so that compatibility, safety, and durability of the relevant components implanted in the body (particularly the components implanted in the eye, such as tear conduit) may be ensured.
Fig. 1 is a schematic structural view of an implantable tear delivery device according to an embodiment of the present invention.
In the embodiment shown in fig. 1, an implantable tear delivery device is seen, comprising an in-vivo machine 100 arranged inside a patient and an in-vitro machine 200 arranged outside the patient, and said in-vivo machine and said in-vitro machine are connected to each other, wherein,
the in-vivo machine 100 includes: an in-vivo host disposed in the subcutaneous tissue of the patient's ear, having a micropump 150 and a microprocessor 110 connected (shown in the figure as being connected by a micropump drive circuit 155) to the micropump; a saliva conduit 151 connected to the patient's parotid canal, which is connected to the inlet of the micropump; a tear conduit 152 connected to the lacrimal gland of the patient, connected to the outlet of the micropump; a wireless energy receiving module 180;
the extracorporeal machine 200 includes: a power supply unit including a wireless energy supply module 280 corresponding to the wireless energy receiving module; and a regulating unit 250 in communication with the microprocessor.
The implantable tear delivery device provided by the embodiments of the present invention can efficiently and reliably provide supplemental wetting for the human eye.
It is noted that relational terms such as first and second, and the like, are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Moreover, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the statement "comprises one" does not exclude that an additional identical element is present in a process, method, article or apparatus that comprises the element.
In the description herein, it should be noted that "mounted," "connected," and "coupled" are to be construed broadly, and may be, for example, fixedly connected, detachably connected, or integrally connected, unless otherwise specifically indicated and defined; can be mechanical connection, electrical connection, magnetic connection, or communication connection; the two components can be directly connected or indirectly connected through an intermediate medium, or can be communicated inside the two components, or can be connected wirelessly or in a wired way. The specific meaning of the terms herein may be understood by those of ordinary skill in the art as the case may be.
In the description of elements herein, a plurality of juxtaposed features connected by "and/or" is meant to encompass one or more (or one or more) of these juxtaposed features. For example, the meaning of "a first element and/or a second element" is: one or more of the first element and the second element, i.e., only the first element, or only the second element, or both the first element and the second element (both present).
The various embodiments provided in this invention may be combined with each other as desired, e.g., features of any two, three or more embodiments may be combined with each other to form new embodiments of the invention, which are also within the scope of the invention unless stated otherwise or contradicted by skill.
The foregoing description of the exemplary embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any modifications, equivalents, and variations which fall within the spirit and scope of the invention are intended to be included in the scope of the invention.
Claims (10)
1. An implantable tear delivery device comprising an in-vivo machine disposed within a patient and an in-vitro machine disposed outside the patient, and wherein the in-vivo machine and the in-vitro machine are connected to each other, wherein,
the in-vivo machine includes: an in-vivo host disposed in subcutaneous tissue of a patient's ear, having a micropump and a microprocessor connected to the micropump; a saliva conduit connected to a patient's parotid canal, connected to an inlet of the micropump; a tear conduit connected to the lacrimal gland of the patient, connected to an outlet of the micropump; a wireless energy receiving module;
the extracorporeal machine comprises: a power supply unit including a wireless energy supply module corresponding to the wireless energy receiving module; and the regulation and control unit is in communication connection with the microprocessor.
2. The implantable tear delivery device of claim 1,
an outlet of the tear duct at an end thereof connected to the lacrimal gland of the patient is provided with a semipermeable membrane allowing only one-way flow from the tear duct to the lacrimal gland of the patient.
3. The implantable tear delivery device of claim 1,
at least a portion of the outer surface of the extracorporeal machine is provided with a flexible buffer layer.
4. The implantable tear delivery device of claim 1,
the external surface of the external machine is provided with a concave shape which is adapted to the shape of the body surface of the patient.
5. The implantable tear delivery device of claim 1,
the regulation and control unit comprises: a speed adjusting knob for adjusting the saliva conveying speed.
6. The implantable tear delivery device of claim 1,
the regulation and control unit comprises: a transmission speed indicator light for displaying the saliva transmission speed.
7. The implantable tear delivery device of claim 1,
the power supply unit includes: an in vitro battery.
8. The implantable tear delivery device of claim 7,
the wireless energy supply module includes: a wireless energy supply circuit connected to the extracorporeal battery.
9. The implantable tear delivery device of claim 7,
the power supply unit includes: and the battery management circuit is used for managing the charge and discharge of the external battery.
10. The implantable tear delivery device of claim 7,
the regulation and control unit comprises: and the power indicator is used for indicating the residual power of the external battery.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211164810 | 2022-09-23 | ||
| CN2022111648101 | 2022-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117297868A true CN117297868A (en) | 2023-12-29 |
Family
ID=89280443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311227874.6A Pending CN117297868A (en) | 2022-09-23 | 2023-09-21 | Implantable tear delivery device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117297868A (en) |
-
2023
- 2023-09-21 CN CN202311227874.6A patent/CN117297868A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6795975B2 (en) | Nasal stimulation devices and methods | |
| US7780623B2 (en) | Implantable pump apparatuses | |
| US20070100443A1 (en) | Intraocular lens adapted for accommodation via electrical signals | |
| JP2017185286A (en) | Device and method for opening an airway | |
| US20140261425A1 (en) | Wearable Positive Airway Pressure (PAP) with Primary and Bolus Airflow | |
| US6591140B2 (en) | Apparatus and system for stimulating mouth muscles | |
| US9919140B2 (en) | Implantable oxygenator with self-contained electrolyte | |
| KR20120020103A (en) | An apparatus and method for controlling the negative pressure in a wound | |
| US20160067099A1 (en) | A portable device for treating meniere's disease and similar conditions | |
| KR20130089241A (en) | Medical device comprising an artificial contractile structure | |
| US11511112B2 (en) | Wearable medical device | |
| US9901433B2 (en) | Medical device comprising an artificial contractile structure | |
| CN117297868A (en) | Implantable tear delivery device | |
| US20100314415A1 (en) | Hands-free hydration system for non-ambulatory users | |
| CN208176753U (en) | A kind of invisible nasal cavity filter | |
| CN117813134A (en) | Inner ear device with passageway and conductive member | |
| CN215020336U (en) | Ophthalmic surgery postoperative care device | |
| RU195989U1 (en) | DELIVERY SYSTEM FOR MOISTURIZING LIQUID TO LIPS OF SUBJECT | |
| CN218420205U (en) | Eye wetting device for facial paralysis patient | |
| CN216365529U (en) | Artificial tear conveying device | |
| CN215606581U (en) | Prepackage type intraocular lens implantation device for cataract patient | |
| CN215351366U (en) | Tracheal fistula nursing equipment | |
| CN210355476U (en) | Miniature negative pressure drainage device | |
| CN211561492U (en) | Breathing mask for clinical ophthalmic surgery | |
| CN211750280U (en) | Artificial eye with split artificial eye piece |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |